Inhaled chemotherapy in lung cancer: Safety concerns of nanocomplexes delivered

Therapeutic Delivery

Volumn 3, Issue 9, 2012, Pages 1021-1023

  Zarogoulidis, Paul ^a   Gialeli, Chrisostomi ^b,c   Karamanos, Nikos K ^b,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

Author keywords

health safety; inhaled chemotherapy; nanoparticles; toxicity

Indexed keywords

ACETIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CARBON MONOXIDE; CORTICOSTEROID; DENDRIMER; DNA; EPIDERMAL GROWTH FACTOR; GONADORELIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; NANOCARRIER; NANOMATERIAL; POLYMER; SILICON DIOXIDE; TUMOR NECROSIS FACTOR ALPHA;

AEROSOL; BRONCHOSPASM; COMET ASSAY; COUGHING; CYTOKINE PRODUCTION; DNA DAMAGE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG TRANSPORT; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG DIFFUSION; LUNG EDEMA; LUNG HEMORRHAGE; LUNG LAVAGE; NANOTECHNOLOGY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARTICLE SIZE; PEAK EXPIRATORY FLOW; PNEUMONIA; PRIORITY JOURNAL; REVIEW;

EID: 84865718327     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.77     Document Type: Review

References (25)

1. Maynard AD. Don't define nanomaterials. Nature 475(7354), 31 (2011).
2. US FDA. Reporting Format for Nanotechnology-Related Information in CMC Review. Office of Pharmaceutical Science, Silver Spring, MD, USA (2010).
3. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 4(4), 273-282 (2008).
4. Brouwer N, Weda M, van Riet-Nales D, de Kaste D. Nanopharmaceuticals: implications for the European pharmacopoeia. Pharmeuropa 22, 5-7 (2010).
5. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2008). (Pubitemid 351556021)
6. Zarogoulidis P, Papanas N, Kouliatsis G, Spyratos D, Zarogoulidis K, Maltezos E. Inhaled insulin: too soon to be forgotten? J. Aerosol Med. Pulm. Drug Deliv. 24(5), 213-223 (2011).
7. Zarogoulidis P, Eleftheriadou E, Sapardanis I et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest. New Drugs 30(4), 1628-1640 (2011).
8. Lebhardt T, Roesler S, Uusitalo HP, Kissel T. Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation. Eur. J. Pharm. Biopharm. 78(1), 90-96 (2011).
9. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 19(10), 900-914 (2011).
10. Yang W, Peters JI, Williams RO III. Inhaled nanoparticles - a current review. Int. J. Pharm. 356(1-2), 239-247 (2008).
11. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 30(20), 3476-3485 (2009).
12. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br. J. Cancer 68(6), 1146-1149 (1993). (Pubitemid 23356667)
13. Gautam A, Koshkina N. Paclitaxel (taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr. Cancer Drug Targets 3(4), 287-296 (2003). (Pubitemid 36944262)
14. Otterson GA, Villalona-Calero MA, Hicks W et al. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin. Cancer Res. 16(8), 2466-2473 (2010).
15. Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J. Aerosol Med. 19(3), 385-391 (2006). (Pubitemid 44735394)
16. Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp. Biol. Med. (Maywood) 229(11), 1169-1176 (2004). (Pubitemid 39602260)
17. El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm. Res. 26(7), 1752-1763 (2009).
18. Zarogoulidis P, Chatzaki E, Porpodis K et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int. J. Nanomed. 7, 1551-1572 (2012).
19. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56(6), 588-599 (2003). (Pubitemid 37491710)
20. Margaris KN, Black RA. Modelling the lymphatic system: challenges and opportunities. J. R. Soc. Interface 9(69), 601-612 (2012).
21. Selting K, Waldrep JC, Reinero C et al. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J. Aerosol Med. Pulm. Drug Deliv. 21(3), 255-268 (2008).
22. Bosquillon C. Drug transporters in the lung - do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99(5), 2240-2255 (2010).
23. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat. Rev. Cancer 6(8), 583-592 (2006). (Pubitemid 44140857)
24. Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv. Drug Deliv. Rev. 63(6), 441-455 (2011).
25. Arora S, Rajwade JM, Paknikar KM. Nanotoxicology and in vitro studies: the need of the hour. Toxicol. Appl. Pharmacol. 258(2), 151-165 (2012).